Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Study Will Evaluate the Use of Nintedanib in Slowing Lung Fibrosis in Patients With Pulmonary Infiltrates Related to COVID-19 (ENDCOV-I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04619680
Recruitment Status : Recruiting
First Posted : November 6, 2020
Last Update Posted : December 17, 2020
Sponsor:
Collaborator:
Boehringer Ingelheim
Information provided by (Responsible Party):
Maria L Padilla, Icahn School of Medicine at Mount Sinai

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 2021